3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity

Lian Xue; Da Hua Shi; Jitendra R. Harjani; Fei Huang; Julia G. Beveridge; Tamir Dingjan; Kung Ban; Sarah Diab; Sandra Duffy; Leonardo Lucantoni; Sabine Fletcher; Francis C.K. Chiu; Scott Blundell; Katherine Ellis; Stuart A. Ralph; Grennady Wirjanata; Silvia Teguh; Rintis Noviyanti; Marina Chavchich; Darren Creek; Ric N. Price; Jutta Marfurt; Susan A. Charman; Matthew E. Cuellar; Jessica M. Strasser; Jayme L. Dahlin; Michael A. Walters; Michael D. Edstein; Vicky M. Avery; Jonathan B. Baell

doi:10.1021/acs.jmedchem.8b01799

3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity

Lian Xue, Da Hua Shi, Jitendra R. Harjani, Fei Huang, Julia G. Beveridge, Tamir Dingjan, Kung Ban, Sarah Diab, Sandra Duffy, Leonardo Lucantoni, Sabine Fletcher, Francis C.K. Chiu, Scott Blundell, Katherine Ellis, Stuart A. Ralph, Grennady Wirjanata, Silvia Teguh, Rintis Noviyanti, Marina Chavchich, Darren CreekRic N. Price, Jutta Marfurt, Susan A. Charman, Matthew E. Cuellar, Jessica M. Strasser, Jayme L. Dahlin, Michael A. Walters, Michael D. Edstein, Vicky M. Avery, Jonathan B. Baell

Institute for Therapeutics Discovery and Development

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

A series of 3,3′-disubstituted 5,5′-bi(1,2,4-triazine) derivatives was synthesized and screened against the erythrocytic stage of Plasmodium falciparum 3D7 line. The most potent dimer, 6k, with an IC ₅₀ (50% inhibitory concentration) of 0.008 μM, had high in vitro potency against P. falciparum lines resistant to chloroquine (W2, IC ₅₀ = 0.0047 ± 0.0011 μM) and artemisinin (MRA1240, IC ₅₀ = 0.0086 ± 0.0010 μM). Excellent ex vivo potency of 6k was shown against clinical field isolates of both P. falciparum (IC ₅₀ = 0.022-0.034 μM) and Plasmodium vivax (IC ₅₀ = 0.0093-0.031 μM) from the blood of outpatients with uncomplicated malaria. Despite 6k being cleared relatively rapidly in mice, it suppressed parasitemia in the Peters 4-day test, with a mean ED ₅₀ value (50% effective dose) of 1.47 mg kg ^-1 day ^-1 following oral administration. The disubstituted triazine dimer 6k represents a new class of orally available antimalarial compounds of considerable interest for further development.

Original language	English (US)
Journal	Journal of Medicinal Chemistry
DOIs	https://doi.org/10.1021/acs.jmedchem.8b01799
State	Published - Mar 14 2019

Bibliographical note

Publisher Copyright:
© Copyright 2019 American Chemical Society.

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1021/acs.jmedchem.8b01799

Find It

Find It at U of M Libraries

Cite this

Xue, L., Shi, D. H., Harjani, J. R., Huang, F., Beveridge, J. G., Dingjan, T., Ban, K., Diab, S., Duffy, S., Lucantoni, L., Fletcher, S., Chiu, F. C. K., Blundell, S., Ellis, K., Ralph, S. A., Wirjanata, G., Teguh, S., Noviyanti, R., Chavchich, M., ... Baell, J. B. (2019). 3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b01799

Xue, L, Shi, DH, Harjani, JR, Huang, F, Beveridge, JG, Dingjan, T, Ban, K, Diab, S, Duffy, S, Lucantoni, L, Fletcher, S, Chiu, FCK, Blundell, S, Ellis, K, Ralph, SA, Wirjanata, G, Teguh, S, Noviyanti, R, Chavchich, M, Creek, D, Price, RN, Marfurt, J, Charman, SA, Cuellar, ME, Strasser, JM, Dahlin, JL, Walters, MA, Edstein, MD, Avery, VM & Baell, JB 2019, '3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity', Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b01799

@article{251b0d7e757f4bd2be55bdaf38b7cd64,

title = "3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity",

abstract = " A series of 3,3′-disubstituted 5,5′-bi(1,2,4-triazine) derivatives was synthesized and screened against the erythrocytic stage of Plasmodium falciparum 3D7 line. The most potent dimer, 6k, with an IC 50 (50% inhibitory concentration) of 0.008 μM, had high in vitro potency against P. falciparum lines resistant to chloroquine (W2, IC 50 = 0.0047 ± 0.0011 μM) and artemisinin (MRA1240, IC 50 = 0.0086 ± 0.0010 μM). Excellent ex vivo potency of 6k was shown against clinical field isolates of both P. falciparum (IC 50 = 0.022-0.034 μM) and Plasmodium vivax (IC 50 = 0.0093-0.031 μM) from the blood of outpatients with uncomplicated malaria. Despite 6k being cleared relatively rapidly in mice, it suppressed parasitemia in the Peters 4-day test, with a mean ED 50 value (50% effective dose) of 1.47 mg kg -1 day -1 following oral administration. The disubstituted triazine dimer 6k represents a new class of orally available antimalarial compounds of considerable interest for further development. ",

author = "Lian Xue and Shi, {Da Hua} and Harjani, {Jitendra R.} and Fei Huang and Beveridge, {Julia G.} and Tamir Dingjan and Kung Ban and Sarah Diab and Sandra Duffy and Leonardo Lucantoni and Sabine Fletcher and Chiu, {Francis C.K.} and Scott Blundell and Katherine Ellis and Ralph, {Stuart A.} and Grennady Wirjanata and Silvia Teguh and Rintis Noviyanti and Marina Chavchich and Darren Creek and Price, {Ric N.} and Jutta Marfurt and Charman, {Susan A.} and Cuellar, {Matthew E.} and Strasser, {Jessica M.} and Dahlin, {Jayme L.} and Walters, {Michael A.} and Edstein, {Michael D.} and Avery, {Vicky M.} and Baell, {Jonathan B.}",

year = "2019",

month = mar,

day = "14",

doi = "10.1021/acs.jmedchem.8b01799",

language = "English (US)",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

}

TY - JOUR

T1 - 3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity

AU - Xue, Lian

AU - Shi, Da Hua

AU - Harjani, Jitendra R.

AU - Huang, Fei

AU - Beveridge, Julia G.

AU - Dingjan, Tamir

AU - Ban, Kung

AU - Diab, Sarah

AU - Duffy, Sandra

AU - Lucantoni, Leonardo

AU - Fletcher, Sabine

AU - Chiu, Francis C.K.

AU - Blundell, Scott

AU - Ellis, Katherine

AU - Ralph, Stuart A.

AU - Wirjanata, Grennady

AU - Teguh, Silvia

AU - Noviyanti, Rintis

AU - Chavchich, Marina

AU - Creek, Darren

AU - Price, Ric N.

AU - Marfurt, Jutta

AU - Charman, Susan A.

AU - Cuellar, Matthew E.

AU - Strasser, Jessica M.

AU - Dahlin, Jayme L.

AU - Walters, Michael A.

AU - Edstein, Michael D.

AU - Avery, Vicky M.

AU - Baell, Jonathan B.

PY - 2019/3/14

Y1 - 2019/3/14

N2 - A series of 3,3′-disubstituted 5,5′-bi(1,2,4-triazine) derivatives was synthesized and screened against the erythrocytic stage of Plasmodium falciparum 3D7 line. The most potent dimer, 6k, with an IC 50 (50% inhibitory concentration) of 0.008 μM, had high in vitro potency against P. falciparum lines resistant to chloroquine (W2, IC 50 = 0.0047 ± 0.0011 μM) and artemisinin (MRA1240, IC 50 = 0.0086 ± 0.0010 μM). Excellent ex vivo potency of 6k was shown against clinical field isolates of both P. falciparum (IC 50 = 0.022-0.034 μM) and Plasmodium vivax (IC 50 = 0.0093-0.031 μM) from the blood of outpatients with uncomplicated malaria. Despite 6k being cleared relatively rapidly in mice, it suppressed parasitemia in the Peters 4-day test, with a mean ED 50 value (50% effective dose) of 1.47 mg kg -1 day -1 following oral administration. The disubstituted triazine dimer 6k represents a new class of orally available antimalarial compounds of considerable interest for further development.

AB - A series of 3,3′-disubstituted 5,5′-bi(1,2,4-triazine) derivatives was synthesized and screened against the erythrocytic stage of Plasmodium falciparum 3D7 line. The most potent dimer, 6k, with an IC 50 (50% inhibitory concentration) of 0.008 μM, had high in vitro potency against P. falciparum lines resistant to chloroquine (W2, IC 50 = 0.0047 ± 0.0011 μM) and artemisinin (MRA1240, IC 50 = 0.0086 ± 0.0010 μM). Excellent ex vivo potency of 6k was shown against clinical field isolates of both P. falciparum (IC 50 = 0.022-0.034 μM) and Plasmodium vivax (IC 50 = 0.0093-0.031 μM) from the blood of outpatients with uncomplicated malaria. Despite 6k being cleared relatively rapidly in mice, it suppressed parasitemia in the Peters 4-day test, with a mean ED 50 value (50% effective dose) of 1.47 mg kg -1 day -1 following oral administration. The disubstituted triazine dimer 6k represents a new class of orally available antimalarial compounds of considerable interest for further development.

UR - http://www.scopus.com/inward/record.url?scp=85062831950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062831950&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b01799

DO - 10.1021/acs.jmedchem.8b01799

M3 - Article

C2 - 30715882

AN - SCOPUS:85062831950

SN - 0022-2623

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

ER -

3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this